Jochen Probst
Overview
Explore the profile of Jochen Probst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sebastian M, Schroder A, Scheel B, Hong H, Muth A, von Boehmer L, et al.
Cancer Immunol Immunother
. 2019 Feb;
68(5):799-812.
PMID: 30770959
CV9201 is an RNActive-based cancer immunotherapy encoding five non-small cell lung cancer-antigens: New York esophageal squamous cell carcinoma-1, melanoma antigen family C1/C2, survivin, and trophoblast glycoprotein. In a phase I/IIa...
2.
Kubler H, Scheel B, Gnad-Vogt U, Miller K, Schultze-Seemann W, Vom Dorp F, et al.
J Immunother Cancer
. 2015 Jun;
3:26.
PMID: 26082837
Background: CV9103 is a prostate-cancer vaccine containing self-adjuvanted mRNA (RNActive®) encoding the antigens PSA, PSCA, PSMA, and STEAP1. This phase I/IIa study evaluated safety and immunogenicity of CV9103 in patients...
3.
Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, et al.
Int J Cancer
. 2014 Dec;
137(2):372-84.
PMID: 25530186
Protein- and peptide-based tumor vaccines depend on strong adjuvants to induce potent immune responses. Here, we demonstrated that a recently developed novel adjuvant based on a non-coding, long-chain RNA molecule,...
4.
Kramps T, Probst J
Wiley Interdiscip Rev RNA
. 2013 Jul;
4(6):737-49.
PMID: 23893949
Twenty years after the demonstration that messenger RNA (mRNA) was expressed and immunogenic upon direct injection in mice, the first successful proof-of-concept of specific protection against viral infection in small...
5.
Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam T, Verdurmen W, et al.
RNA Biol
. 2011 Jun;
8(4):627-36.
PMID: 21654214
Insertional mutagenesis and the inherent risk of malignancy compromise the clinical use of DNA-based therapies. Being a transient copy of genetic material, mRNA is a safe alternative, overcoming this limitation....
6.
Fotin-Mleczek M, Duchardt K, Lorenz C, Pfeiffer R, Ojkic-Zrna S, Probst J, et al.
J Immunother
. 2010 Dec;
34(1):1-15.
PMID: 21150709
Direct vaccination with messenger RNA (mRNA) molecules encoding tumor-associated antigens is a novel and promising approach in cancer immunotherapy. The main advantage of using mRNA for vaccination is that the...
7.
Debus H, Baumhof P, Probst J, Kissel T
J Control Release
. 2010 Sep;
148(3):334-43.
PMID: 20854856
Nucleic acid based therapies have so far mainly been focused on plasmid DNA (pDNA), small interfering RNA (siRNA), antisense and immunostimulatory oligonucleotides. Messenger RNA (mRNA) was the subject of only...
8.
Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee H, et al.
Eur J Immunol
. 2006 Oct;
36(10):2807-16.
PMID: 17013976
Stabilized synthetic RNA oligonucleotides (ORN) and protected messenger RNA (mRNA) were recently discovered to possess an immunostimulatory capacity through their recognition by TLR 7 and 8. We wanted to find...
9.
Probst J, Brechtel S, Scheel B, Hoerr I, Jung G, Rammensee H, et al.
Genet Vaccines Ther
. 2006 May;
4:4.
PMID: 16732888
The rapid degradation of ribonucleic acids (RNA) by ubiquitous ribonucleases limits the efficacy of new therapies based on RNA molecules. Therefore, our aim was to characterize the natural ribonuclease activities...
10.
Carralot J, Weide B, Schoor O, Probst J, Scheel B, Teufel R, et al.
Genet Vaccines Ther
. 2005 Aug;
3:6.
PMID: 16115316
Background: Anti-tumor vaccines targeting the entire tumor antigen repertoire represent an attractive immunotherapeutic approach. In the context of a phase I/II clinical trial, we vaccinated metastatic melanoma patients with autologous...